Liquidia Corporation (NASDAQ: LQDA) Stock Competitors & Peer Comparison
See LQDA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LQDA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LQDA | $90.22 | +0.89% | 8B | 644.43 | $0.14 | N/A |
| RPRX | $56.77 | -0.86% | 25.2B | 10.81 | $5.25 | +1.60% |
| CORT | $110.77 | +2.61% | 12B | 316.49 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $76.06 | -0.59% | 5.8B | 84.51 | $0.90 | N/A |
| TRLV | $8.75 | -2.78% | 1.5B | -20.83 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CUVL | $6.68 | -0.65% | 336.6M | N/A | N/A | N/A |
| LFMD | $3.56 | +4.71% | 172.2M | -7.12 | -$0.50 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
LQDA vs RPRX Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while RPRX trades at $56.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas RPRX's P/E ratio is 10.81. In terms of profitability, LQDA's ROE is +0.47%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, LQDA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
LQDA vs CORT Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, CORT has a market cap of 12B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while CORT trades at $110.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas CORT's P/E ratio is 316.49. In terms of profitability, LQDA's ROE is +0.47%, compared to CORT's ROE of +0.08%. Regarding short-term risk, LQDA is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
LQDA vs WBA Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas WBA's P/E ratio is -1.64. In terms of profitability, LQDA's ROE is +0.47%, compared to WBA's ROE of -0.42%. Regarding short-term risk, LQDA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
LQDA vs KNSA Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while KNSA trades at $76.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas KNSA's P/E ratio is 84.51. In terms of profitability, LQDA's ROE is +0.47%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, LQDA is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check KNSA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
LQDA vs TRLV Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while TRLV trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas TRLV's P/E ratio is -20.83. In terms of profitability, LQDA's ROE is +0.47%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, LQDA is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
LQDA vs HROWL Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas HROWL's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, LQDA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
LQDA vs HROWM Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas HROWM's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, LQDA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check HROWM's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
LQDA vs CUVL Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while CUVL trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas CUVL's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to CUVL's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
LQDA vs LFMD Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while LFMD trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas LFMD's P/E ratio is -7.12. In terms of profitability, LQDA's ROE is +0.47%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, LQDA is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
LQDA vs LFMDP Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while LFMDP trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, LQDA's ROE is +0.47%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, LQDA is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
LQDA vs CIRC Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while CIRC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas CIRC's P/E ratio is -1.64. In terms of profitability, LQDA's ROE is +0.47%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, LQDA is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
LQDA vs RAD Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas RAD's P/E ratio is -0.05. In terms of profitability, LQDA's ROE is +0.47%, compared to RAD's ROE of +2.76%. Regarding short-term risk, LQDA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
LQDA vs GLTO Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LQDA's ROE is +0.47%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, LQDA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
LQDA vs SCYX Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while SCYX trades at $5.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas SCYX's P/E ratio is -1.53. In terms of profitability, LQDA's ROE is +0.47%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, LQDA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SCYX's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
LQDA vs NSRX Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while NSRX trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas NSRX's P/E ratio is -4.80. In terms of profitability, LQDA's ROE is +0.47%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, LQDA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check NSRX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
LQDA vs SDEV Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while SDEV trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas SDEV's P/E ratio is -0.18. In terms of profitability, LQDA's ROE is +0.47%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, LQDA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SDEV's competition here
Biofrontera Inc. (NASDAQ: BFRI)
LQDA vs BFRI Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while BFRI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas BFRI's P/E ratio is -1.19. In terms of profitability, LQDA's ROE is +0.47%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, LQDA is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
LQDA vs CJJD Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LQDA's ROE is +0.47%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LQDA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
LQDA vs SSY Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas SSY's P/E ratio is -2.86. In terms of profitability, LQDA's ROE is +0.47%, compared to SSY's ROE of -0.09%. Regarding short-term risk, LQDA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
LQDA vs POM Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while POM trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas POM's P/E ratio is -0.17. In terms of profitability, LQDA's ROE is +0.47%, compared to POM's ROE of +0.16%. Regarding short-term risk, LQDA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check POM's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
LQDA vs PAVS Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while PAVS trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas PAVS's P/E ratio is -0.07. In terms of profitability, LQDA's ROE is +0.47%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, LQDA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check PAVS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
LQDA vs HKPD Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while HKPD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas HKPD's P/E ratio is -7.01. In terms of profitability, LQDA's ROE is +0.47%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, LQDA is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check HKPD's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
LQDA vs AIXC Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while AIXC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas AIXC's P/E ratio is -0.09. In terms of profitability, LQDA's ROE is +0.47%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, LQDA is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
LQDA vs MDVL Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LQDA's ROE is +0.47%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LQDA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
LQDA vs ATNFW Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, LQDA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
LQDA vs BGMSP Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LQDA's ROE is +0.47%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, LQDA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
LQDA vs BGMS Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while BGMS trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas BGMS's P/E ratio is -0.26. In terms of profitability, LQDA's ROE is +0.47%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, LQDA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
LQDA vs AZNH Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LQDA's ROE is +0.47%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LQDA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
LQDA vs LFLYW Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LQDA's ROE is +0.47%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LQDA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
LQDA vs SBFMW Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas SBFMW's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, LQDA is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
LQDA vs ESRX Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LQDA's ROE is +0.47%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LQDA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
LQDA vs POZN Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, POZN has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas POZN's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to POZN's ROE of +0.61%. Regarding short-term risk, LQDA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
LQDA vs OREX Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, OREX has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas OREX's P/E ratio is -0.14. In terms of profitability, LQDA's ROE is +0.47%, compared to OREX's ROE of -0.54%. Regarding short-term risk, LQDA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
LQDA vs IPXL Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LQDA's ROE is +0.47%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LQDA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
LQDA vs CPD Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, CPD has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas CPD's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +0.47%, compared to CPD's ROE of N/A. Regarding short-term risk, LQDA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
LQDA vs SHPG Comparison August 2026
Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LQDA stands at 8B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LQDA is priced at $90.22 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LQDA currently has a P/E ratio of 644.43, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LQDA's ROE is +0.47%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LQDA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check SHPG's competition here